Who Gets Dark Spots on the Face? Causes, Skin Tone, and Next Steps

Acne marks are common, but not every mark after a pimple is pigment

A flat brown, tan, gray-brown, or sometimes pink mark that remains after a pimple has healed may be PIH. The inflammation involved in acne can stimulate pigment production or change where pigment sits in the skin. Picking, squeezing, scrubbing, or repeatedly applying irritating products may intensify inflammation and extend the cycle. PIH is not the same as an atrophic or raised acne scar: a scar changes skin texture or contour, whereas a pigment mark is primarily a color change. The two can appear together, so the word “scar” in everyday speech does not tell you which is present.

People with deeper skin tones often experience PIH more visibly and for longer, but lighter skin can show post-acne discoloration too. The severity of the original breakout is not the only factor. A small inflamed blemish can leave a mark, especially if it is manipulated or repeatedly irritated; a painful deeper breakout can leave both pigment and texture changes. New marks continuing to appear usually mean the original trigger—active acne, irritation, or another inflammatory condition—still needs attention.

For facial acne marks, prevention and treatment of active acne are separate jobs. If pimples keep forming, fading only the marks will not stop new ones. Choose acne care that you can tolerate and use consistently; avoid stacking multiple strong exfoliants because a burning, peeling routine can generate additional irritation. A dermatologist can advise when acne is painful, scarring, persistent, or not responding to over-the-counter approaches. The guide Korean Skincare for Post-Blemish Marks covers routine selection after a blemish, while the Post-Acne Marks (PIH/PIE) hub separates flat color changes from post-acne concerns more broadly.

There is no one serum that is appropriate for every post-breakout mark. Vitamin C derivatives, niacinamide, tranexamic acid, alpha arbutin, azelaic acid, and retinoids appear in skincare conversations, but the strength of evidence, formulation, concentration, skin tolerance, and suitability vary. The ingredient list on a cosmetic item does not establish that it will clear an individual mark. Start by limiting friction and picking, keeping cleansing gentle, using moisturizer if needed, and applying a suitable sunscreen on exposed skin. If a spot is raised, changing, bleeding, painful, or unlike the others, treat it as a question for a clinician rather than a cosmetic target.

For shoppers comparing formats after they already understand the issue, a serum and a cream are different delivery formats, not proof of different clinical outcomes. A serum can be easier to layer in one routine; a cream may combine a leave-on step with a richer vehicle. The more relevant questions are whether the formula suits your current routine, whether its active ingredients duplicate steps you already use, and whether you can follow the directions without stinging or persistent redness.

Sun spots, age spots, and freckles: exposure and age change the odds

Solar lentigines, often called sun spots or age spots, are flat areas of increased pigment associated with long-term sun exposure. They often appear on parts of the body with substantial lifetime exposure, such as the face and backs of the hands. They become more common with age because exposure accumulates, not because every older person develops them. People with more sun exposure, a history of sunburns, or use of tanning devices may notice them earlier or more often, although individual susceptibility varies.

Freckles are different. Ephelides commonly begin earlier in life, cluster on sun-exposed areas, and may darken during sunnier months or become less noticeable when exposure decreases. Genetics influence who is more likely to freckle. Freckles are not automatically a problem to remove; for many people they are a normal feature. A new or changing spot should still be evaluated on its own features rather than assumed to be a freckle because nearby freckles are present.

The phrase “age spot” can sound reassuring, but it is a nickname, not a diagnosis. A benign lentigo, a seborrheic keratosis, a mole, and a skin cancer can all be described by a shopper as a brown spot. AAD recommends that a dermatologist examine an age spot before treatment because some skin cancers can mimic harmless spots. This precaution matters before laser, peel, freezing, or strong fading products, which can alter a lesion’s appearance and delay recognition.

Sun exposure is not limited to vacation or intentional tanning. Repeated short periods outside, walking a dog, sitting by a bright window, commuting, gardening, and outdoor work can add up. UV exposure can also darken existing marks. Sunscreen, hats, shade, and protective clothing work together; a sunscreen alone does not turn the rest of the day into unlimited safe exposure. For American shoppers, look for the U.S. label’s “Broad Spectrum” claim and SPF 30 or higher, then follow the package directions. The product’s Korean SPF or PA rating alone does not show that the U.S. Broad Spectrum claim is present.

If your concern is mostly cumulative sun exposure and you want to compare products, start with the store’s Sunscreen hub and read Korean Sunscreen and Hyperpigmentation: Why SPF Matters. A hub helps you browse; the label and the fit of the formula to your routine remain the decision points. The Korean sunscreen guide covers format considerations without turning sunscreen into a promise that spots will disappear.

How skin tone affects visibility and how long a mark lasts

Melanin is the pigment that contributes to skin, hair, and eye color. After some kinds of inflammation, pigment may increase in the affected area; how visible the change looks depends partly on a person’s baseline skin tone and how that skin responds. PIH is often more noticeable and can last longer in darker skin tones, but it can occur in anyone. A lighter complexion does not guarantee that a blemish, burn, or dermatitis will leave no mark.

It is useful to distinguish incidence from visibility. A mark can be present but less noticeable on one person and more noticeable on another. That difference does not mean the darker mark reflects poor hygiene, greater damage, or a need for stronger products. It also does not mean that people with deeper complexions should use harsher treatments. Irritation itself can create additional discoloration, and aggressive procedures may carry pigment-related risks that deserve discussion with a clinician experienced in the patient’s skin tone.

Skin tone categories are rough descriptions, not diagnostic instruments. Fitzpatrick skin type was designed around how skin tends to burn or tan in response to sunlight; it is not a complete scale of race, ancestry, pigment biology, or dermatologic risk. Two people with similar visible complexions can react differently to inflammation or treatment. A clinician should account for personal history and observed skin response, not infer a safe procedure from a label alone.

For melasma, visible light may be relevant in addition to ultraviolet exposure. AAD guidance for people with darker skin tones describes tinted sunscreen containing iron oxide as an option to help protect against visible light, alongside broad-spectrum SPF 30 or higher and other label criteria. This is a targeted consideration, not a claim that any tinted product prevents or clears melasma. The shade must be usable for the person, and the finished formula still needs an appropriate label and comfortable application.

Color terms such as brown, gray, blue-gray, or pink can sometimes give a dermatologist clues about pigment depth or the nature of the change, but shoppers should not use shade matching to self-diagnose. Lighting, camera settings, makeup, and natural variation alter how color appears in photos. A mark that looks dark in a selfie may look different in daylight; a melanoma may not match a textbook picture. Compare only under similar lighting if tracking a known, diagnosed benign mark, and send a clinician images only as supporting context, not as a substitute for examination.

Media often show “dark spots” on a narrow range of faces and then imply one universal treatment. In practice, clinicians need information from people across a wider range of skin tones, and patients should be able to discuss discoloration without being told that it is a trivial cosmetic issue. A mark can affect confidence, routines, and willingness to be photographed, even when it is medically benign. It is reasonable to want to understand it; it is also reasonable to choose not to treat a harmless feature.

How to choose skincare without assuming every spot is the same

Once a clinician has identified a benign pigment concern and you have addressed the main trigger, a cosmetic formula may be one optional part of a routine. Ingredient names alone are not enough to judge likely benefit. The final formula, concentration, pH, vehicle, packaging, application frequency, stability, and adherence all matter. Studies may examine a prescription ingredient, a single active, or a product combination that differs from the product on a shelf. A mechanistic explanation—such as an ingredient interacting with pathways related to pigment—does not prove that a finished cosmetic product will produce a visible outcome.

Vitamin C derivatives are a good example of why precision matters. “Vitamin C” describes a family of molecules with different stability and formulation properties. Evidence for one derivative cannot automatically be transferred to another derivative or to every serum with “Vita C” in the name. For an overview of the differences, see Vitamin C Derivatives in Korean Skincare: Forms and Evidence. Treat the article as ingredient education, not a guarantee that a particular product will treat melasma, PIH, or a changing lesion.

Niacinamide appears in many formulas and is often used in routines for general skin goals. Concentration and finished-formula context still matter. A product’s presence in a “brightening” collection is not proof of a direct spot-fading effect. Our evidence-oriented guide Niacinamide for Dark Spots: What the Evidence Actually Supports separates plausible mechanisms from the conclusions human evidence can support. If you are browsing, the Niacinamide collection is a category page, not a treatment plan.

Tranexamic acid (TXA) is another ingredient shoppers often consider for uneven-looking tone, especially when melasma is part of the discussion. Topical cosmetic products are not interchangeable with oral medication or clinician-directed treatment. The evidence depends on use, formulation, and population, and an ingredient label does not tell you whether an individual should use it. Read Tranexamic Acid in Skincare: What to Know Before You Try It for ingredient context, then seek medical advice for diagnosis or pregnancy-related decisions.

Alpha arbutin, licorice derivatives, azelaic acid, retinoids, and hydroquinone appear in different cosmetic and medical contexts. Their regulatory status and evidence vary. In the United States, hydroquinone products marketed as over-the-counter skin-lightening products raise specific regulatory and safety issues; do not assume a product from any seller is appropriate because it appears online. Prescription therapy, treatment of melasma, and post-procedure care belong with a licensed clinician. Avoid products with undeclared steroids or mercury and do not use liquid bleach; AAD warns against unsafe skin-lightening products.

Shopping should answer a narrow question: Does this product fit the cause my clinician identified, my current routine, my sensitivity, and the package directions? Consider whether it duplicates an existing active, whether the packaging suits the formula, whether you can use it consistently, and whether the seller provides a current ingredient list. If you cannot tell, ask the retailer or clinician for clarification. “More popular,” “viral,” or “K-beauty” does not establish that a product suits your individual skin.

How long can a dark mark last?

There is no single timeline because the cause and depth differ. The AAD says a post-inflammatory spot a few shades darker than a person’s natural skin tone may take roughly 6 to 12 months to fade after the underlying cause is controlled. Deeper pigment can take years. That estimate applies to certain flat PIH patterns; it does not promise that every mark fades in that window, nor does it apply automatically to melasma, sun spots, moles, scars, or a lesion that has not been diagnosed.

Ongoing triggers change the clock. New pimples can leave fresh marks while older marks fade. Continued irritation can create a new PIH cycle. Sun exposure can darken some existing marks. Melasma may fluctuate or recur, particularly with triggers. A persistent spot does not necessarily mean that you have failed or that you should use a stronger product. It may mean the cause is still active, the mark is deeper, the treatment is not appropriate, or the original assumption about the diagnosis needs review.

Track a known benign mark in consistent lighting, at the same distance, and without filters or makeup. A monthly photo may be easier to interpret than daily inspection. Write down the date, products used, and any irritation. Do not use tracking photos to postpone care when the lesion is new or changing; in that situation, documentation can support an appointment but should not replace it.

Set an outcome that is observable and fair. You might be aiming for fewer new marks because acne is controlled, less irritation, better consistency with sun protection, or gradual change in a clinician-identified pigment mark. “Gone by next week” is not a safe standard. Nor should a person judge success only by a heavily edited before-and-after image from a different lighting setup. Skin has normal variation, and a treatment decision can be successful even when the mark remains visible.

If you are using a clinician-directed treatment and see no progress, do not increase frequency or strength on your own. Ask how long the plan is intended to run, what response to expect, which side effects require stopping, and what alternative diagnosis might explain a lack of response. A follow-up gives the clinician a chance to adjust the plan rather than letting frustration turn into overuse.